The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2
infection with symptoms consistent with COVID-19. An anticipated total of 132 participants
will be randomly divided almost equally into 2 groups: one group will receive Dipyridamole ER
200mg/ Aspirin 25mg orally/enterally along with the standard of care and the other group with
receive the standard of care only but no Dipyridamole ER 200mg/ Aspirin 25mg. Participants
will be screened, enrolled, receive treatment, and followed for 28 days. The clinical and
laboratory outcomes of all the participants enrolled in the study will be evaluated at the
end of the study to explore if there is any difference in the outcomes between 2 groups.